Open an account

Biomerica

BMRA · NASDAQ

$1.72−$0.0413 (−2.35%)TodayMarket closed ·
Prev close $1.76

About BMRA

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 53 full-time employees. The firm develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product is developed on the inFoods technology platform, which is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases.

Employees
53
Headquarters
Irvine, California
Listed
Mar 17, 1980
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
biomerica.com

BMRA key statistics

Market cap
7.90M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
20.54K
Volume
5.97K
Open price
$1.73
High today
$1.79
Low today
$1.60
52 Week high
$3.21
52 Week low
$1.45

Biomerica (BMRA) at a glance

As of Oct 20, 2026, Biomerica (BMRA) shares are priced at $1.72, giving the company a market cap of 7.90M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.60 and $1.79. The current price is 7.4% above the day's low and 3.9% below its high.

Volume so far is 5.97K shares, below the average of 20.54K shares a day.

Over the past year Biomerica has ranged from $1.45 to $3.21, and now sits 15% of the way up that range.

Biomerica met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q3 FY26 it reported -$0.44 per share against an estimate of $0.00.

BMRA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 2.0% on average.

  1. Q2 FY21: reported -$1.04 per share against an estimate of -$0.7956
  2. Q3 FY21: reported -$1.20 per share against an estimate of -$0.6528
  3. Q4 FY21: reported -$0.9718 per share against an estimate of -$0.8976
  4. Q1 FY22: reported -$0.96 per share against an estimate of -$0.9792
  5. Q2 FY22: reported -$0.72 per share against an estimate of -$0.6528
  6. Q2 FY23: reported -$0.12 per share against an estimate of $0.00
  7. Q2 FY24: reported -$0.09 per share against an estimate of $0.00
  8. Q3 FY26: reported -$0.44 per share against an estimate of $0.00

BMRA news

  • Caroline Ryan

    Deal Dispatch: Carets Corp Explores Strategic Alternatives, nVent Electric Buys Maverick Power for $1.75 Billion, BioXcel Bankruptcy

  • Press releaseBusiness Wire

    ConsumerDirect Expands Executive Team with Appointment of Gary Lu, CPA as Chief Financial Officer

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Crude Oil Moves Higher; Travelers Earnings Beat Estimates

  • Avi Kapoor

    Nasdaq Down Over 2%; Abbott Laboratories Posts Upbeat Earnings

  • Watching Biomerica; Co Named In 'Research Shows Blood Test May Provide Personalized Dietary Therapy For Patients With Irritable Bowel Syndrome'; Michigan Medicine And Cleveland Clinic Study Finds Blood Test-Guided Diet Reduces Abdominal Pain In IBS Patients

  • Apple, Rivian, Unitedhealth, Biomerica, Tesla: Why These 5 Stocks Are On Investors' Radars Today

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

Similar companies

Companies in the same industry as Biomerica

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.